While GLP-1 medications do not show up on standard drug screenings, they leave a positive and measurable mark on your metabolic health
In 2018 Zheng and colleagues compared the efficacy of SGLT-2i, GLP-1 agonists, and DPP4i on mortality and cardiovascular end points using a network meta-analysis of 236 trials with 176 310 participants, finding that SGLT-2 inhibitors were associated with reduction in all MIs [HR 0.86 (95% CI 0.770.97)] and nonfatal MIs [HR 0.84 (95% CI 0.720.98)] compared with the control groups (Zheng et al., 2018)
For example, in one Medicare Plus Blue PPO formulary we reviewed, Trulicity was listed as a tier 3 drug
According to one study, regular semaglutide use can produce an average of approximately 10.9 percent total body weight loss in six months
doi: 10.7759/cureus.45181
Ask your diabetes team what items you can keep available for reversing low blood sugar in an emergency situation